Published in final edited form as:

Eur J Med Chem. 2009 January ; 44(1): 322–331. doi:10.1016/j.ejmech.2008.02.026.

Conformationally Constrained Analogues of *N*-(4-*t*-Butylbenzyl)-*N*-(4-Methylsulfonylaminobenzyl)Thiourea as TRPV1 Antagonists

HyungChul Ryu^a, Ju-Ok Lim^a, Dong Wook Kang^a, Larry V. Pearce^b, Richard Tran^b, Attila Toth^b, Jeewoo Lee^{*,a}, and Peter M. Blumberg^b

^aLaboratory of Medicinal Chemistry, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 151-742, Korea

^bLaboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA

Abstract

A series of bicyclic analogues having indan and tetrahydronaphthalene templates in the A-region were designed as conformationally constrained analogues of our previously reported potent TRPV1 antagonists (**1**, **3**). The activities for rat TRPV1 of the conformationally restricted analogues were moderately or markedly diminished, particularly in the case of the tetrahydronaphthalene analogues. The analysis indicated that steric constraints at the benzylic position in the bicyclic analogues were an important factor for their unfavorable interaction with the receptor.

Keywords

TRPV1 antagonists; analgesic; conformationally constrained analogues

1. Introduction

The transient receptor potential V1 (TRPV1) receptor¹ is a molecular integrator of nociceptive stimuli, including protons,² heat,³ inflammatory mediators such as anandamide⁴ and lipoxygenase products,⁵ and vanilloids such as capsaicin (CAP)⁶ and resiniferatoxin (RTX)⁷. The receptor functions as a non-selective cation channel with high Ca²⁺ permeability and its activation leads to an increase in intracellular Ca²⁺ that results in excitation of primary sensory neurons and ultimately the central perception of pain.

TRPV1 antagonists have attracted much attention as promising drug candidates for inhibiting the transmission of nociceptive signaling from the periphery to the CNS and for blocking other pathological states associated with this receptor. They have thus emerged as novel and promising analgesic and antiinflammatory agents, particularly for chronic pain and inflammatory hyperalgesia.⁸ The number of antagonists reported continues to increase and some of them have entered clinical trials.^{9,10}

Previously, we have demonstrated that a series of *N*-4-(methylsulfonylaminobenzyl) thiourea analogues were effective antagonists of the action of capsaicin on rat TRPV1.^{11–14} A prototype antagonist (**1**) showed high binding affinity and potent antagonism ($K_i = 63$ nM and $K_{i(ant)} = 54$ nM in rTRPV1/CHO).¹¹ We further found that 3-substituents of the 4-

*To whom correspondence should be addressed. Phone: 82-2-880-7846 Fax: 82-2-888-0649 jeewoo@snu.ac.kr.

(methylsulfonylamino)phenyl group in the A-region affected the extent of agonism/antagonism. Thus, the 3-fluoro derivative **2** ($K_i = 53.5$ nM, $K_{i(\text{ant})} = 9.2$ nM in rTRPV1/CHO) was a potent antagonist not only of capsaicin stimulation of rTRPV1 but also of stimulation by temperature and pH.¹¹ Conversely, the 3-methoxy derivative **3** showed a shift to partial agonism ($K_i = 51$ nM, 17% agonism and 84% antagonism in rTRPV1/CHO) while the binding affinity remained unaffected.¹² In order to optimize the *in vitro* activities of 4-methylsulfonamide TRPV1 antagonists, we have investigated extensively their structure activity relationships as a function of the structural regions designated as the A, B and C-regions.^{15–17}

As part of our continuing effort to further optimize the receptor potency and antagonist efficacy of lead antagonists, we have investigated conformationally constrained analogues of the lead antagonists with the goal of stabilizing a favorable “bioactive conformation”. The target compounds were designed to impose conformational restriction between the benzylic position and the phenyl ring through incorporation of a carbon linker as shown in Figure 1, providing indan and tetrahydronaphthalene templates. In the interest of synthetic accessibility, parent compounds **1** and **3** were chosen to evaluate the effect of the conformational constraint.

2. Chemistry

The synthetic strategy for preparation of the target compounds is shown in Figure 2. The target thioureas were synthesized by the coupling of 4-*t*-butylbenzyl isothiocyanate with the bicyclic amines of the A-region moieties, which were obtained from the corresponding ketones via oxime intermediates. The ketones were prepared either by benzylic oxidation of *N*-Boc substituted indan or by nitration of appropriately substituted 1-indanone/ α -tetralone.

The syntheses of the target compounds having 5-(methylsulfonylamino)indanyl and 6-(methylsulfonylamino)-1,2,3,4-tetrahydro-1-naphthyl moieties in the A-region are outlined in Scheme 1. Benzylic oxidation of *N*-Boc substituted bicycles (**6**, **7**), prepared from commercially available 5-aminoindan (**4**) or tetrahydronaphthalene, by pyridinium chlorochromate provided 1-indanone (**8**) and 5-oxo-tetrahydronaphthalene (**9**) templates. After deprotection and mesylation, ketones of **12** and **13** were converted to the corresponding amines (**16**, **17**) via oximes, which were condensed with 4-*t*-butylbenzyl isothiocyanate to afford the final thiourea compounds (**18**, **19**).

The syntheses of methoxy substituted analogues of **18** and **19** are shown in Schemes 2 and 3. Nitration¹⁸ of commercially available 4-methoxy-1-indanone (**20**) and 5-methoxy-1-tetralone (**21**) provided the key intermediates, 4-methoxy-5-nitro-1-indanone (**22**) and 5-methoxy-6-nitro-1-tetralone (**23**), respectively. As by-products from para-nitration, 7-nitro-1-indanone and 8-nitro-1-tetralone were also isolated, respectively. The structures of isomers were assigned based on the comparison of chemical shifts and NOE enhancement of protons adjacent to the methoxy group. For example, the H₇ and H₈ protons of 5-methoxy-6-nitro-1-tetralone (**23**) shifted downfield compared to the H₆ and H₇ protons of 5-methoxy-8-nitro-1-tetralone (**23'**). Whereas only one NOE enhancement by OCH₃ irradiation of **23** (6-nitro isomer) was observed, the two enhancements in **23'** (8-nitro isomer) were found (see ref 19). Nitro groups of **22** and **23** were converted to the corresponding methylsulfonylamino groups (**26** and **27**) in two steps. The final 4-methoxy-1-indanyl (**32**) and 5-methoxy-1-naphthyl (**33**) compounds were prepared from **26** and **27** by the protocol described in Scheme 1.

The syntheses of 6-methoxy-1-indanyl (**46**) and 7-methoxy-1-naphthyl (**47**) compounds as shown in Scheme 3 were carried out by a strategy similar to that described in Scheme 2,

starting from 6-methoxy-1-indanone (**20**) and 7-methoxy-1-tetralone (**21**). The structures of the geometric isomers resulting from nitration of **34** and **35** were readily confirmed by the values of the *ortho* or *para* coupling constants.

3. Result and Discussion

The binding affinities and potencies as agonists/antagonists of the synthesized TRPV1 ligands were assessed *in vitro* by a binding competition assay with [³H]RTX and by a functional ⁴⁵Ca²⁺ uptake assay using rat TRPV1 heterologously expressed in Chinese hamster ovary (CHO) cells, as previously described.¹³ The results are summarized in Table 1, together with the potencies of the previously reported antagonists **1** and **3**.¹⁵

The conformational restriction of the parent thiourea **1** by bridging between the benzylic position in the B-region and the phenyl in the A-region with a two (or three) carbon linker provided the two bicycles, indan (**18**) and tetrahydronaphthalene (**19**), respectively. These compounds revealed that the constraint led to the moderate loss of receptor activity compared to the parent antagonist. The binding affinities of **18** and **19** were reduced by 10-fold and 25-fold compared to **1**; their potencies as antagonists decreased by a similar extent, 14-fold and 50-fold, respectively. The reduction in activity for the tetrahydronaphthalene analogue (**19**) was greater than that for the indan analogue (**18**).

Although conformational restriction might shift the conformations of the bicyclic compounds away from the “bioactive conformation”, the steric environment at the benzylic position appears to be dominant for favorable interaction with the receptor. We previously reported that incorporation of a methyl group, particularly with an (*R*)-configuration, at the benzylic position of the A-region in compound **1** enhanced specific binding to the receptor.¹⁷ For example, the (*R*)- α -methyl analogue of compound **1** showed high potency with a $K_i = 41$ nM for receptor binding and $K_{i(\text{ant})} = 4.5$ nM for antagonism of capsaicin stimulated calcium uptake. However, more bulky substituents such as ethyl, isopropyl, phenyl and benzyl groups resulted in modest to dramatic decreases in binding affinities and antagonistic potencies, with the antagonist potencies diminishing as the size of the substituents increased, Et > *i*-Pr > Bn > Ph. Our current findings, that the sterically more demanding tetrahydronaphthalene analogue (**19**) caused greater reduction in receptor activity compared to indan (**18**), are consistent with these observations.

To further investigate the conformationally constrained bicycles, we synthesized the conformationally constrained analogues of the parent compound **3** with a 3-methoxy group in the A-region. Depending upon the direction of cyclization and the length of the linker, there are four possible bicyclic analogues, as shown in Figure 1.

The indan analogs representing the 4-isomer (**32**) and the 6-isomer (**46**) were prepared. As with the analogues described above, their activities were reduced compared to that of the parent compound. The binding affinities of the 4-isomer (**32**) and the 6-isomer (**46**) decreased by 36-fold and 67-fold, respectively, and their potencies as antagonists were markedly reduced. The two tetrahydronaphthalene analogues, the 5-isomer (**33**) and the 7-isomer (**47**), similarly showed a reduction in receptor activities. The binding affinities of the 5-isomer (**33**) and the 7-isomer (**47**) decreased by 35-fold and 137-fold, respectively, and their potencies as antagonists were again markedly diminished, or, for compound **47**, undetectable over the range of concentrations that were tested. As observed with compounds **18** and **19**, the receptor activities of the tetrahydronaphthalenes were reduced more than those of the indans and this may be attributed to the more sterically demanding tetrahydronaphthalene ring. Interestingly, the 4- or 5-isomers were found to be more potent

than their corresponding 6- or 7-isomers in the bicyclic analogues, and this positional effect of substitution is currently under investigation.

It should be noted that, at high (10–30 μ M) ligand concentrations, interpretation of inhibitory responses on TRPV1 is somewhat less straightforward because of the possibility of superimposed specific and non-specific mechanisms of antagonism. However, for this series of ligands no change in the nature of the responses from antagonist to agonist was observed, as evidenced by the agonism assays. In any case, we believe that the ligand binding assays, because they circumvent issues of calcium processing, desensitization, and rates of ligand penetration into the cells, provide the most robust measure of the structure activity relations for receptor – ligand recognition.

4. Conclusion

We have investigated conformationally constrained analogues of the potent TRPV1 antagonists (**1**, **3**), designed with the intention of stabilizing the bioactive conformation, and have analyzed their structure-activity relationships. The six bicyclic analogues, representing indan and tetrahydronaphthalene templates, were designed and synthesized employing regioselective nitration and reductive amination of benzylic ketones. Unfortunately, the synthesized bicyclic analogues showed moderate or weak receptor activities compared to parent compounds. The SAR analysis, together with our previous findings, suggests that the loss in activity may be attributed to steric restrictions at the benzylic position of the bicyclic analogues resulting in unfavorable interactions with the receptor.

5. Experimental

5.1. General

All chemical reagents were commercially available. Melting points were determined on a melting point Buchi B-540 apparatus and are uncorrected. Silica gel column chromatography was performed on silica gel 60, 230 – 400 mesh, Merck. Proton NMR spectra were recorded on a JEOL JNM-LA 300 at 300 MHz. Chemical shifts are reported in ppm units with Me_4Si as a reference standard. Mass spectra were recorded on a VG Trio-2 GC-MS. Combustion analyses were performed on an EA 1110 Automatic Elemental Analyzer, CE Instruments.

5.1.1. 5,6,7,8-Tetrahydro-2-naphthylamine (5)—1,2,3,4-Tetrahydronaphthalene (3.965 g, 30 mmol) was added to a stirred suspension of copper(II) nitrate hydrate (5.62 g, 30 mmol) and acetic anhydride (10 mL) in diethyl ether (20 mL). The reaction mixture was stirred at room temperature until consumption of the starting material was completed, as monitored by TLC (ca. 3 h). The mixture was filtered through celite by washing with additional ether and the filtrate was concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel using EtOAc:hexanes (1:10) as eluant to give a mixture of mono-nitrated products as a yellow oil (2.55 g, 48%). The compound (2.55 g, 57.6 mmol) in MeOH (50 mL) was treated with 10% palladium on carbon (0.3 g) and hydrogenated under a balloon of hydrogen for 1 h. The reaction mixture was filtered through celite and the filtrate was concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel using EtOAc:hexanes (1:5) as eluant to provide 2-naphthylamine (**5**) as a white solid (1.144 g, 54%) along with its isomer, 1-naphthylamine (**5'**) as a red oil (0.657 g, 31%).

2-Naphthylamine (**5**): R_f = 0.250 (EtOAc:hexanes=1:5), mp = 33 °C

^1H NMR (CDCl_3) δ 6.85 (d, 1 H, J = 7.8 Hz, H-4), 6.47 (dd, 1 H, J = 7.8, 2.4 Hz, H-3), 6.41 (d, 1 H, J = 2.4 Hz, H-1), 3.47 (bs, 2 H, NH_2), 2.66 (m, 4 H, H-5 & H-8), 1.75 (m, 4 H, H-6 & H-7).

1-Naphtylamine (**5'**): R_f = 0.375 (EtOAc:hexanes=1:5)

^1H NMR (CDCl_3) δ 6.93 (t, 1 H, J = 7.6 Hz, H-3), 6.52 (m, 2 H, H-2 & H-4), 3.55 (bs, 2 H, NH_2), 2.73 (t, 2 H, J = 6.1 Hz, H-5), 2.45 (t, 2 H, J = 6.1 Hz, H-8), 1.7–1.9 (m, 4 H, H-6 & H-7).

5.1.2. *tert*-Butyl *N*-(indan-5-yl)carbamate (6**)**—A solution of 5-aminoindan (**4**) (3 g, 30 mmol) in CH_2Cl_2 (50 mL) was treated with triethylamine (8.36 mL, 60 mmol) and di-*tert*-butyl dicarbonate (7.857 g, 36 mmol), and stirred at room temperature for 3 h. The reaction mixture was diluted with H_2O and extracted with EtOAc several times. The combined organic layers were washed with H_2O and brine, dried over MgSO_4 , filtered, and the filtrate was concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel using EtOAc:hexanes (1:10) as eluant to provide **6** as a white solid (7.0 g, 100%): mp = 71 °C, ^1H NMR (CDCl_3) δ 7.33 (bs, 1 H, H-4), 7.11 (d, 1 H, J = 8.0 Hz, H-7), 6.99 (dd, 1 H, J = 1.7, 8.0 Hz, H-6), 6.41 (bs, 1 H, NHCO), 2.85 (m, 4 H, H-1 & H-3), 2.05 (m, 2 H, H-2), 1.51 (s, 9 H, $\text{C}(\text{CH}_3)_3$).

5.1.3. *tert*-Butyl *N*-(5,6,7,8-tetrahydro-2-naphthyl)carbamate (7**)**—This compound was obtained from **5** by following the procedure described above to afford a white solid with a quantitative yield: mp = 87 °C, ^1H NMR (CDCl_3) δ 7.14 (bs, 1 H, H-1), 6.98 (m, 2 H, H-3 & H-4), 6.33 (bs, 1 H, NH), 2.71 (m, 4 H, H-5 & H-8), 1.76 (m, 4 H, H-6 & H-7), 1.50 (s, 9 H, $\text{C}(\text{CH}_3)_3$).

5.1.4. *tert*-Butyl *N*-(1-indanone-5-yl)carbamate (8**)**—To a suspension of pyridinium chlorochromate (8.622 g, 40 mmol) and 4 Å molecular sieve (10 g) in CH_2Cl_2 (200 mL) was added **6** (4.666 g, 20 mmol) portionwise. The reaction mixture was refluxed for 24 h, cooled and diluted with ether. After stirring for 1 h, the mixture was filtered through celite and the filtrate was concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel using EtOAc:hexanes (1:3) as eluant to provide **8** as a white solid (3.46 g, 70%): mp = 176 °C, ^1H NMR (CDCl_3) δ 7.76 (bs, 1 H, H-4), 7.67 (d, 1 H, J = 8.3 Hz, H-7), 7.13 (dd, 1 H, J = 1.7, 8.3 Hz, H-6), 6.81 (bs, 1 H, NHCO), 3.09 (t, 2 H, J = 5.6 Hz, H-3), 2.67 (m, 2 H, H-2), 1.54 (s, 9 H, $\text{C}(\text{CH}_3)_3$).

5.1.5. *tert*-Butyl *N*-(5-oxo-5,6,7,8-tetrahydro-2-naphthyl)carbamate (9**)**—This compound was obtained from **7** by following the procedure described above to afford a yellow solid in 65% yield: mp = 135 °C, ^1H NMR (CDCl_3) δ 7.97 (d, 1 H, J = 8.6 Hz, H-4), 7.49 (bs, 1 H, H-1), 7.10 (dd, 1 H, J = 2.2 Hz, H-3), 6.76 (bs, 1 H, NHCO), 2.93 (t, 2 H, J = 6.1 Hz, H-8), 2.61 (t, 2 H, J = 6.1 Hz, H-6), 2.12 (m, 2 H, H-7), 1.53 (s, 9 H, $\text{C}(\text{CH}_3)_3$); IR (KBr) 3311, 1729, 1662, 1604, 1585, 1529 cm^{-1} .

5.1.6. 5-Amino-1-indanone (10**)**—A cooled solution of **8** (3.46 g, 14 mmol) in CH_2Cl_2 (30 mL) at 0 °C was treated with trifluoroacetic acid (6 mL) and stirred at room temperature for 1 h. The mixture was removed *in vacuo*, neutralized with saturated NaHCO_3 solution, and extracted with EtOAc several times. The combined organic layers were washed with H_2O and brine, dried over MgSO_4 , filtered, and the filtrate was concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel using EtOAc:hexanes (1:1) as eluant to give **10** as a yellow solid (1.852 g, 90%): mp = 190 °C, ^1H NMR (CDCl_3)

δ 7.58 (d, 1 H, J = 9.0 Hz, H-7), 6.60 (m, 2 H, H-4 & H-6), 4.21 (bs, 2 H, NH₂), 3.00 (t, 2 H, J = 5.8 Hz, H-3), 2.63 (m, 2 H, H-2).

5.1.7. 6-Amino-1-tetralone (11)—This compound was obtained from **9** by following the procedure described above to afford a yellow solid in 92% yield: mp = 132 °C, ¹H NMR (CDCl₃) δ 7.89 (d, 1 H, J = 8.6 Hz, H-8), 6.54 (dd, 1 H, J = 8.6, 2.2 Hz, H-7), 6.42 (d, 1 H, J = 2.2 Hz, H-5), 4.10 (bs, 2 H, NH₂), 2.83 (t, 2 H, J = 6.1 Hz, H-4), 2.57 (t, 2 H, J = 6.1 Hz, H-2), 2.08 (m, 2 H, H-3).

5.1.8. 5-(Methylsulfonylamino)-1-indanone (12)—A cooled solution of **10** (0.59 g, 4 mmol) in pyridine (4 mL) at 0 °C was treated with methanesulfonyl chloride (0.62 mL, 8 mmol) and stirred at room temperature for 2 h. The reaction mixture was diluted with H₂O and extracted with EtOAc several times. The combined organic layers were washed with H₂O and brine, dried over MgSO₄, filtered, and the filtrate was concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel using EtOAc:hexanes (2:1) as eluant to give **12** as a brown solid (0.8 g, 88%): mp = 222 °C, ¹H NMR (CDCl₃) δ 7.75 (d, 1 H, J = 8.3 Hz, H-7), 7.36 (d, 1 H, J = 1.7 Hz, H-4), 7.09 (dd, 1 H, J = 1.7, 8.3 Hz, H-6), 6.87 (s, 1 H, NHSO₂), 3.1–3.2 (m, 5 H, H-3 & SO₂CH₃), 2.71 (m, 2 H, H-2).

5.1.9. 6-(Methylsulfonylamino)-1-tetralone (13)—This compound was obtained from **11** by following the procedure described above to afford a white solid in 93% yield: mp = 171 °C, ¹H NMR (CDCl₃) δ 8.04 (d, 1 H, J = 8.5 Hz, H-8), 7.09 (d, 1 H, J = 2.2 Hz, H-5), 7.04 (dd, 1 H, J = 8.5, 2.2 Hz, H-7), 6.69 (s, 1 H, NHSO₂), 3.11 (s, 3 H, SO₂CH₃), 2.96 (t, 2 H, J = 6.1 Hz, H-4), 2.64 (t, 2 H, J = 6.1 Hz, H-2), 2.14 (m, 2 H, H-3).

5.1.10. 5-(Methylsulfonylamino)-1-indanone oxime (14)—A mixture of **12** (0.675 g, 3 mmol) and hydroxylamine hydrochloride (0.417 g, 6 mmol) in pyridine (3 mL) was heated at 70 °C for 3 h. The reaction mixture was cooled to room temperature, diluted with H₂O, and extracted with EtOAc several times. The combined organic layers were washed with H₂O and brine, dried over MgSO₄, filtered, and the filtrate was concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel using EtOAc:hexanes (1:1) as eluant to give **14** as a white solid (0.684 g, 95%): mp = 188 °C, ¹H NMR (CDCl₃) δ 7.62 (d, 1 H, J = 8.3 Hz, H-7), 7.23 (d, 1 H, J = 1.7 Hz, H-4), 7.03 (dd, 1 H, J = 1.7, 8.3 Hz, H-6), 6.42 (s, 1 H, NHSO₂), 3.02–3.1 (m, 5 H, H-3 & SO₂CH₃), 2.94–3.0 (m, 2 H, H-2).

5.1.11. 6-(Methylsulfonylamino)-1-tetralone oxime (15)—This compound was obtained from **13** by following the procedure described above to afford a white solid in 93% yield: mp = 192 °C, ¹H NMR (CDCl₃) δ 7.90 (d, 1 H, J = 8.5 Hz, H-8), 7.02 (d, 1 H, J = 2.2 Hz, H-5), 6.99 (dd, 1 H, J = 8.5, 2.2 Hz, H-7), 6.33 (s, 1 H, NHSO₂), 3.04 (s, 3 H, SO₂CH₃), 2.79 (t, 2 H, J = 6.1 Hz, H-4), 2.75 (t, 2 H, J = 6.1 Hz, H-2), 1.87 (m, 2 H, H-3).

5.1.12. 5-(Methylsulfonylamino)-1-indanylamine (16)—A suspension of **14** (0.48 g, 2 mmol) and 10% palladium on carbon (100 mg) in MeOH (20 mL) was treated with concentrated hydrochloric acid (10 drops) and hydrogenated under a balloon of hydrogen for 6 h. The reaction mixture was neutralized with solid NaHCO₃, filtered and the filtrate was concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel using CH₂Cl₂:MeOH (5:1) as eluant to give **16** as a brown solid (0.443 g, 98%): mp = 148 °C, ¹H NMR (CDCl₃) δ 7.28 (d, 1 H, J = 8.3 Hz, H-7), 7.10 (bs, 1 H, H-4), 7.04 (dd, 1 H, J = 1.7, 8.3 Hz, H-6), 4.36 (t, 1 H, J = 7.1 Hz, H-1), 3.32 (bs, 2 H, NH₂), 2.98 (s, 3 H, SO₂CH₃), 2.95 (m, 1 H, H-3a), 2.78 (m, 1 H, H-3b), 2.50 (m, 1 H, H-2a), 1.72 (m, 1 H, H-2b).

5.1.13. 6-(Methylsulfonylamino)-1,2,3,4-tetrahydro-1-naphthylamine (17)—This compound was obtained from **13** by following the procedure described above to afford a white solid in 98% yield: mp = 198 °C, ¹H NMR (DMSO-d₆) δ 8.25 (bs, 3 H, NH₂ & NHSO₂), 7.46 (d, 1 H, *J* = 8.5 Hz, H-8), 7.05 (dd, 1 H, *J* = 8.5, 2.2 Hz, H-7), 6.97 (d, 1 H, *J* = 2.2 Hz, H-5), 4.28 (t, 1 H, *J* = 5.6 Hz, H-1), 2.97 (s, 3 H, SO₂CH₃), 2.70 (m, 2 H, H-4), 1.6–2.1 (m, 4 H, H-2 & H-3).

5.1.14. N-(4-*tert*-Butylbenzyl)-N'-[5-(methylsulfonylamino)-1-indanyl]thiourea (18)—A mixture of **16** (0.226 g, 1 mmol) and 4-*tert*-butylbenzyl isothiocyanate (0.205 g, 1 mmol) in DMF (4 mL) was stirred at room temperature for 2 h. The reaction mixture was diluted with H₂O and extracted with EtOAc several times. The combined organic layers were washed with H₂O and brine, dried over MgSO₄, filtered, and the filtrate was concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel with EtOAc:hexanes (1:1) as eluant to give **18** as a white solid (0.363 g, 84%): mp = 172 °C, ¹H NMR (CDCl₃) δ 7.38 (d, 2 H, *J* = 8.3 Hz, *t*-BuPh), 7.25 (d, 2 H, *J* = 8.3 Hz, *t*-BuPh), 7.1–7.2 (m, 2 H, H-7 & H-4), 6.95 (dd, 1 H, *J* = 1.7, 8.3 Hz, H-6), 6.48 (s, 1 H, NHSO₂), 6.22 (bs, 1 H, NH), 5.77 (bs, 2 H, NH & H-1), 4.55 (bs, 2 H, CH₂NHCS), 2.99 (s, 3 H, SO₂CH₃), 2.75–2.9 (m, 2 H, H-3), 2.65 (m, 1 H, H-2a), 1.84 (m, 1 H, H-2b), 1.32 (s, 9 H, C(CH₃)₃); IR (KBr) 3433, 2961, 1628, 1545, 1489, 1322, 1148 cm⁻¹; MS *m/z* 432 (MH⁺); Anal. Calcd for C₂₂H₂₉N₃O₂S₂: C, 61.22; H, 6.77; N, 9.74; S, 14.86. Found: C, 61.43; H, 6.80; N, 9.70; S, 14.81.

5.1.15. N-(4-*tert*-Butylbenzyl)-N'-[6-(methylsulfonylamino)-1,2,3,4-tetrahydro-1-naphthyl]thiourea (19)—This compound was obtained from **17** by following the procedure described above to afford a white solid in 86% yield: mp = 131 °C, ¹H NMR (CDCl₃) δ 7.38 (d, 2 H, *J* = 8.3 Hz, *t*-BuPh), 7.2–7.25 (m, 3 H, *t*-BuPh, H-8), 6.90–6.95 (m, 2 H, H-5 & H-7), 6.38 (s, 1 H, NHSO₂), 6.18 (bs, 1 H, NH), 5.71 (bs, 1 H, NH), 5.50 (bs, 1 H, H-1), 4.51 (bs, 2 H, CH₂NHCS), 3.00 (s, 3 H, SO₂CH₃), 2.72 (m, 2 H, H-4), 2.06 (m, 1 H, H-2a), 1.7–1.9 (m, 3 H, H-3 & H-2b), 1.31 (s, 9 H, C(CH₃)₃); IR (KBr) 3430, 2961, 1616, 1548, 1505, 1394, 1311, 1150 cm⁻¹; MS *m/z* 446 (MH⁺); Anal. Calcd for C₂₃H₃₁N₃O₂S₂: C, 61.99; H, 7.01; N, 9.43; S, 14.39. Found: C, 61.78; H, 7.03; N, 9.39; S, 14.34.

5.1.16. 4-Methoxy-5-nitro-1-indanone (22)—4-Methoxy-1-indanone (**20**) (1.62 g, 10 mmol) was added to a stirred suspension of copper(II) nitrate hydrate (1.88 g, 10 mmol) and acetic anhydride (10 mL) in diethyl ether (20 mL). The reaction mixture was stirred at room temperature until consumption of the starting material was completed, as monitored by TLC (ca. 3 h). The mixture was filtered through celite by washing with additional ether and the filtrate was concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel using EtOAc:hexanes (1:2) as eluant to give the 5-nitro isomer (**22**) as a yellow solid (0.973 g, 47%) along with its 7-nitro isomer (**22'**) as a yellow solid (0.787 g, 38%).

5-Nitro (**22**): R_f = 0.29 (EtOAc:hexanes=1:2), mp = 86 °C

¹H NMR (CDCl₃) δ 7.75 (d, 1 H, *J* = 8.3 Hz, H-6), 7.56 (d, 1 H, *J* = 8.3 Hz, H-7), 4.05 (s, 3 H, OCH₃), 3.27 (t, 2 H, *J* = 6.1 Hz, H-3), 2.80 (m, 2 H, H-2).

7-Nitro (**22'**): R_f = 0.23 (EtOAc:hexanes=1:2), mp = 143 °C

¹H NMR (CDCl₃) δ 7.82 (d, 1 H, *J* = 8.5 Hz, H-6), 7.01 (d, 1 H, *J* = 8.5 Hz, H-5), 4.00 (s, 3 H, OCH₃), 3.04 (t, 2 H, *J* = 6.1 Hz, H-3), 2.79 (m, 2 H, H-2).

5.1.17. 5-Methoxy-6-nitro-1-tetralone (23)—This compound, along with its 8-nitro isomer (**23'**), was obtained from 5-methoxy-1-tetralone (**21**) by following the procedure described above.

6-Nitro (**23**): 46% yield, R_f = 0.50 (EtOAc:hexanes=1:2), yellow solid, mp = 76 °C

^1H NMR (CDCl_3) δ 7.91 (d, 1 H, J = 8.5 Hz, H-8), 7.67 (d, 1 H, J = 8.5 Hz, H-7), 3.94 (s, 3 H, OCH_3), 3.05 (t, 2 H, J = 6.1 Hz, H-4), 2.71 (t, 2 H, J = 6.1 Hz, H-2), 2.18 (m, 2 H, H-3)

8-Nitro (**23'**): 42% yield, R_f = 0.39 (EtOAc:hexanes=1:2), yellow solid, mp = 106 °C

^1H NMR (CDCl_3) δ 7.41 (d, 1 H, J = 8.8 Hz, H-7), 6.96 (d, 1 H, J = 8.8 Hz, H-6), 3.87 (s, 3 H, OCH_3), 2.90 (t, 2 H, J = 6.1 Hz, H-4), 2.71 (t, 2 H, J = 6.1 Hz, H-2), 2.14 (m, 2 H, H-3).

5.1.18. 5-Amino-4-methoxy-1-indanone (24)—A suspension of **22** (1.035 g, 5 mmol) and 10% palladium on carbon (150 mg) in MeOH (50 mL) was hydrogenated under a balloon of hydrogen for 1 h. The reaction mixture was filtered through celite and the filtrate was concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel using EtOAc:hexanes (1:1) as eluant to give **24** as a yellow solid (0.78 g, 88%): mp = 148 °C, ^1H NMR (CDCl_3) δ 7.39 (d, 1 H, J = 8.1 Hz, H-7), 6.71 (d, 1 H, J = 8.1 Hz, H-6), 4.39 (bs, 2 H, NH_2), 3.89 (s, 3 H, OCH_3), 3.11 (t, 2 H, J = 6.1 Hz, H-3), 2.65 (m, 2 H, H-2).

5.1.19. 6-Amino-5-methoxy-1-tetralone (25)—This compound was obtained from **23** by following the procedure described above to afford a white solid in 93% yield: mp = 144 °C, ^1H NMR (CDCl_3) δ 7.74 (d, 1 H, J = 8.5 Hz, H-8), 6.64 (d, 1 H, J = 8.5 Hz, H-7), 4.28 (bs, 2 H, NH_2), 3.75 (s, 3 H, OCH_3), 2.93 (t, 2 H, J = 6.8 Hz, H-4), 2.56 (t, 2 H, J = 6.8 Hz, H-2), 2.08 (m, 2 H, H-3).

5.1.20. 4-Methoxy-5-(methylsulfonylamino)-1-indanone (26)—This compound was obtained from **24** by following the procedure described for the synthesis of **12** to afford a yellow solid in 95% yield: mp = 186 °C, ^1H NMR (CDCl_3) δ 7.61 (d, 1 H, J = 8.3 Hz, H-6), 7.54 (d, 1 H, J = 8.3 Hz, H-7), 7.31 (s, 1 H, NHSO_2), 4.01 (s, 3 H, OCH_3), 3.24 (t, 2 H, J = 6.1 Hz, H-3), 3.10 (m, 3 H, SO_2CH_3), 2.72 (m, 2 H, H-2).

5.1.21. 5-Methoxy-6-(methylsulfonylamino)-1-tetralone (27)—This compound was obtained from **25** by following the procedure described for the synthesis of **12** to afford a white solid in 93% yield: mp = 179 °C, ^1H NMR (CDCl_3) δ 7.89 (d, 1 H, J = 8.8 Hz, H-7), 7.51 (d, 1 H, J = 8.8 Hz, H-8), 7.25 (s, 1 H, NHSO_2), 3.80 (s, 3 H, OCH_3), 3.11 (s, 3 H, SO_2CH_3), 2.97 (t, 2 H, J = 6.1 Hz, H-4), 2.64 (t, 2 H, J = 6.1 Hz, H-2), 2.13 (m, 2 H, H-3).

5.1.22. 4-Methoxy-5-(methylsulfonylamino)-1-indanone oxime (28)—This compound was obtained from **26** by following the procedure described for the synthesis of **14** to afford a white solid in 90% yield: mp = 209 °C, ^1H NMR (CDCl_3) δ 7.50 (d, 1 H, J = 8.3 Hz, H-6), 7.40 (d, 1 H, J = 8.3 Hz, H-7), 7.28 (s, 1 H, NHSO_2), 7.01 (s, 1 H, OH), 3.94 (s, 3 H, OCH_3), 3.18 (t, 2 H, J = 6.1 Hz, H-3), 2.95–3.05 (m, 5 H, SO_2CH_3 & H-2).

5.1.23. 5-Methoxy-6-(methylsulfonylamino)-1-tetralone oxime (29)—This compound was obtained from **27** by following the procedure described for the synthesis of **14** to afford a white solid in 99% yield: mp = 189 °C, ^1H NMR (CDCl_3) δ 7.73 (d, 1 H, J = 8.8 Hz, H-7), 7.42 (d, 1 H, J = 8.8 Hz, H-8), 7.37 (bs, 1 H, OH), 6.99 (s, 1 H, NHSO_2), 3.76 (s, 3 H, OCH_3), 3.06 (s, 3 H, SO_2CH_3), 2.79 (m, 4 H, H-4 & H-2), 1.86 (m, 2 H, H-3).

5.1.24. 4-Methoxy-5-(methylsulfonylamino)-1-indanamine (30)—This compound was obtained from **28** by following the procedure described for the synthesis of **16** to afford a white solid in 98% yield: mp = 218 °C, ^1H NMR (CDCl_3) δ 7.42 (d, 1 H, J = 8.0 Hz, H-6), 7.04 (d, 1 H, J = 8.0 Hz, H-7), 4.33 (t, 1 H, J = 7.3 Hz, H-1), 3.90 (s, 3 H, OCH_3), 2.98 (s, 3 H, SO_2CH_3), 3.10 (ddd, 1 H, H-3a), 2.90 (m, 1 H, H-3b), 2.52 (m, 1 H, H-2a), 1.72 (m, 1 H, H-2b).

5.1.25. 5-Methoxy-6-(methylsulfonylamino)-1,2,3,4-tetrahydro-1-naphthylamine (31)—This compound was obtained from **29** by following the procedure described for the synthesis of **16** to afford a white solid in 98% yield: mp = 132 °C, ^1H NMR (CDCl_3) δ 7.39 (d, 1 H, J = 8.5 Hz, H-7), 7.26 (d, 1 H, J = 8.5 Hz, H-8), 4.88 (bs, 2 H, NH_2), 4.13 (m, 1 H, H-1), 3.75 (s, 3 H, OCH_3), 3.04 (s, 3 H, SO_2CH_3), 2.6–2.9 (m, 2 H, H-4), 2.00 (m, 2 H, H-2), 1.80 (m, 2 H, H-3).

5.1.26. *N*-(4-*tert*-Butylbenzyl)-*N'*-[4-methoxy-5-(methylsulfonylamino)-1-indanyl]thiourea (32)—This compound was obtained from **30** by following the procedure described for the synthesis of **18** to afford a white solid in 90% yield: mp = 96 °C, ^1H NMR (CDCl_3) δ 7.39 (d, 2 H, J = 8.3 Hz, *t*-BuPh), 7.34 (d, 1 H, J = 8.3 Hz, H-6), 7.25 (d, 2 H, J = 8.3 Hz, *t*-BuPh), 6.8–6.9 (m, 1 H, H-7 & NHSO_2), 6.17 (bs, 1 H, NH), 5.72 (bs, 2 H, NH & H-1), 4.55 (bs, 2 H, CH_2NHCS), 3.88 (s, 3 H, OCH_3), 2.85–3.15 (m, 5 H, SO_2CH_3 & H-3), 2.70 (m, 1 H, H-2a), 1.85 (m, 1 H, H-2b), 1.32 (s, 9 H, $\text{C}(\text{CH}_3)_3$); IR (KBr) 3433, 2961, 1635, 1540, 1483, 1312, 1155 cm^{-1} ; MS m/z 462 (MH^+); Anal. Calcd for $\text{C}_{23}\text{H}_{31}\text{N}_3\text{O}_3\text{S}_2$: C, 59.84; H, 6.77; N, 9.10; S, 13.89. Found: C, 60.00; H, 6.81; N, 9.05; S, 13.86.

5.1.27. *N*-(4-*tert*-Butylbenzyl)-*N'*-[5-methoxy-6-(methylsulfonylamino)-1,2,3,4-tetrahydro-1-naphthyl]thiourea (33)—This compound was obtained from **31** by following the procedure described for the synthesis of **18** to afford a white solid in 65% yield: mp = 172 °C, ^1H NMR (CDCl_3) δ 7.40 (d, 2 H, J = 8.0 Hz, *t*-BuPh), 7.34 (d, 1 H, J = 8.4 Hz, H-7), 7.25 (d, 2 H, J = 8.0 Hz, *t*-BuPh), 7.05 (d, 1 H, J = 8.4 Hz, H-8), 6.86 (s, 1 H, NHSO_2), 6.15 (bs, 1 H, NH), 5.71 (bs, 1 H, NH), 5.52 (bs, 1 H, H-1), 4.53 (s, 2 H, CH_2NHCS), 3.76 (s, 3 H, OCH_3), 3.06 (s, 3 H, SO_2CH_3), 2.74 (m, 2 H, H-4), 2.10 (m, 1 H, H-2a), 1.82 (m, 2 H, H-3), 1.70 (m, 1 H, H-2b), 1.34 (s, 9 H, $\text{C}(\text{CH}_3)_3$); IR (KBr) 3434, 2952, 1635, 1555, 1487, 1315, 1152 cm^{-1} ; MS m/z 476 (MH^+); Anal. Calcd for $\text{C}_{24}\text{H}_{33}\text{N}_3\text{O}_3\text{S}_2$: C, 60.60; H, 6.99; N, 8.83; S, 13.48. Found: C, 60.82; H, 7.02; N, 8.79; S, 13.42.

5.1.28. 6-Methoxy-5-nitro-1-indanone (36)—This compound, along with its 7-nitro isomer (**36'**), was obtained from 6-methoxy-1-indanone (**34**) by following the procedure described for the synthesis of **22**.

5-Nitro (**36**): R_f = 0.29 (EtOAc:hexanes=1:2), 22% yield, yellow solid, mp = 174 °C

^1H NMR (CDCl_3) δ 7.81 (s, 1 H, H-4), 7.40 (s, 1 H, H-7), 3.98 (s, 3 H, OCH_3), 3.16 (t, 2 H, J = 6.1 Hz, H-3), 2.80 (m, 2 H, H-2).

7-Nitro (**36'**): R_f = 0.13 (EtOAc:hexanes=1:2), 64% yield, yellow solid, mp = 157 °C

^1H NMR (CDCl_3) δ 7.55 (d, 1 H, J = 8.5 Hz, H-4), 7.33 (d, 1 H, J = 8.5 Hz, H-5), 3.94 (s, 3 H, OCH_3), 3.13 (t, 2 H, J = 6.1 Hz, H-3), 2.78 (m, 2 H, H-2).

5.1.29. 7-Methoxy-6-nitro-1-tetralone (37)—This compound, along with its 8-nitro isomer (**37'**), was obtained from 7-methoxy-1-tetralone (**35**) by following the procedure described for the synthesis of **22**.

6-Nitro (**37**): $R_f = 0.47$ (EtOAc:hexanes=1:2), 20% yield, yellow solid, mp = 116 °C

^1H NMR (CDCl_3) δ 7.72 (s, 1 H, H-5), 7.67 (s, 1 H, H-8), 3.98 (s, 3 H, OCH_3), 2.96 (t, 2 H, $J = 6.1$ Hz, H-4), 2.71 (t, 2 H, $J = 6.1$ Hz, H-2), 2.18 (m, 2 H, H-3).

8-Nitro (**37'**): $R_f = 0.22$ (EtOAc:hexanes=1:2), 76% yield, yellow solid, mp = 121 °C

^1H NMR (CDCl_3) δ 7.35 (d, 1 H, $J = 8.5$ Hz, H-5), 7.20 (d, 1 H, $J = 8.5$ Hz, H-6), 3.89 (s, 3 H, OCH_3), 2.95 (t, 2 H, $J = 6.1$ Hz, H-4), 2.67 (t, 2 H, $J = 6.1$ Hz, H-2), 2.13 (m, 2 H, H-3).

5.1.30. 5-Amino-6-methoxy-1-indanone (38)—This compound was obtained from **36** by following the procedure described for the synthesis of **24** to afford a white solid in 86% yield: mp = 188 °C, ^1H NMR (CDCl_3) δ 7.10 (s, 1 H, H-7), 6.65 (s, 1 H, H-4), 4.44 (bs, 2 H, NH_2), 3.88 (s, 3 H, OCH_3), 2.96 (t, 2 H, $J = 6.1$ Hz, H-3), 2.63 (m, 2 H, H-2).

5.1.31. 6-Amino-7-methoxy-1-tetralone (39)—This compound was obtained from **37** by following the procedure described for the synthesis of **24** to afford a brown solid in 90% yield: mp = 155 °C, ^1H NMR (CDCl_3) δ 7.44 (s, 1 H, H-8), 6.45 (s, 1 H, H-5), 4.30 (bs, 2 H, NH_2), 3.88 (s, 3 H, OCH_3), 2.79 (t, 2 H, $J = 6.1$ Hz, H-4), 2.56 (t, 2 H, $J = 6.1$ Hz, H-2), 2.07 (m, 2 H, H-3).

5.1.32. 6-Methoxy-5-(methylsulfonylamino)-1-indanone (40)—This compound was obtained from **38** by following the procedure described for the synthesis of **12** to afford a yellow solid in 93% yield: mp = 192 °C; ^1H NMR (CDCl_3) δ 7.63 (s, 1 H, H-4), 7.25 (s, 1 H, NHSO_2), 7.23 (s, 1 H, H-7), 3.93 (s, 3 H, OCH_3), 3.10 (m, 5 H, H-3 & SO_2CH_3), 2.70 (m, 2 H, H-2).

5.1.33. 7-Methoxy-6-(methylsulfonylamino)-1-tetralone (41)—This compound was obtained from **39** by following the procedure described for the synthesis of **12** to afford a white solid in 94% yield: mp = 167 °C, ^1H NMR (CDCl_3) δ 7.55 (s, 1 H, H-5), 7.40 (s, 1 H, H-8), 7.14 (s, 1 H, NHSO_2), 3.92 (s, 3 H, OCH_3), 3.06 (s, 3 H, SO_2CH_3), 2.91 (t, 2 H, $J = 6.1$ Hz, H-4), 2.63 (t, 2 H, $J = 6.1$ Hz, H-2), 2.12 (m, 2 H, H-3).

5.1.34. 6-Methoxy-5-(methylsulfonylamino)-1-indanone oxime (42)—This compound was obtained from **40** by following the procedure described for the synthesis of **14** to afford a white solid in 90% yield: mp = 238 °C, ^1H NMR (CDCl_3) δ 7.49 (s, 1 H, H-4), 7.15 (s, 1 H, H-7), 7.06 (s, 1 H, NHSO_2), 6.95 (s, 1 H, OH), 3.90 (s, 3 H, OCH_3), 2.95–3.05 (m, 7 H, H-2, H-3 & SO_2CH_3).

5.1.35. 7-Methoxy-6-(methylsulfonylamino)-1-tetralone oxime (43)—This compound was obtained from **41** by following the procedure described for the synthesis of **14** to afford a white solid in 98% yield: mp = 188 °C, ^1H NMR (CDCl_3) δ 7.42 (s, 1 H, H-5), 7.31 (s, 1 H, H-8), 6.95 (s, 1 H, NHSO_2), 3.86 (s, 3 H, OCH_3), 3.00 (s, 3 H, SO_2CH_3), 2.78 (t, 2 H, $J = 6.1$ Hz, H-4), 2.71 (t, 2 H, $J = 6.1$ Hz, H-2), 2.12 (m, 2 H, H-3).

5.1.36. 6-Methoxy-5-(methylsulfonylamino)-1-indanamine (44)—This compound was obtained from **42** by following the procedure described for the synthesis of **16** to afford a white solid in 91% yield: mp = 220 °C, ^1H NMR (CDCl_3) δ 7.37 (s, 1 H, H-4), 6.93 (s, 1 H, H-7), 4.33 (m, 1 H, H-1), 3.88 (s, 3 H, OCH_3), 2.93 (s, 3 H, SO_2CH_3), 2.70–2.95 (m, 2 H, H-3), 2.52 (m, 1 H, H-2a), 1.68 (m, 1 H, H-2b).

5.1.37. 7-Methoxy-6-(methylsulfonylamino)-1,2,3,4-tetrahydro-1-naphthylamine (45)—This compound was obtained from **43** by following the procedure described for the synthesis of **16** to afford a white solid in 93% yield: mp = 138 °C, ¹H NMR (CDCl₃) δ 7.21 (s, 1 H, H-5), 7.02 (s, 1 H, H-8), 3.92 (m, 1 H, H-1), 3.87 (s, 3 H, OCH₃), 2.94 (s, 3 H, SO₂CH₃), 2.70 (m, 2 H, H-4), 1.6–2.1 (m, 4 H, H-2 & H-3).

5.1.38. N-(4-tert-Butylbenzyl)-N'-[6-methoxy-5-(methylsulfonylamino)-1-indanyl]thiourea (46)—This compound was obtained from **44** by following the procedure described for the synthesis of **18** to afford a white solid in 84% yield: mp = 104 °C, ¹H NMR (CDCl₃) δ 7.38 (d, 2 H, *J* = 8.3 Hz, *t*-BuPh), 7.37 (s, 1 H, H-4), 7.25 (d, 1 H, *J* = 8.3 Hz, *t*-BuPh), 6.91 (s, 1 H, H-7), 6.75 (s, 1 H, NHSO₂), 6.11 (bs, 1 H, NH), 5.80 (bs, 2 H, NH & H-1), 4.58 (bs, 2 H, CH₂NHCS), 3.83 (s, 3 H, OCH₃), 2.95 (s, 3 H, SO₂CH₃), 2.70–2.95 (m, 2 H, H-3), 2.62 (m, 1 H, H-2a), 1.84 (m, 1 H, H-2b), 1.30 (s, 9 H, C(CH₃)₃); IR (KBr) 3430, 2960, 1617, 1540, 1494, 1336, 1147 cm⁻¹; MS *m/z* 462 (MH⁺); Anal. Calcd for C₂₃H₃₁N₃O₃S₂: C, 59.84; H, 6.77; N, 9.10; S, 13.89. Found: C, 60.02; H, 6.80; N, 9.06; S, 13.85.

5.1.39. N-(4-tert-Butylbenzyl)-N'-[7-methoxy-6-(methylsulfonylamino)-1,2,3,4-tetrahydro-1-naphthyl]thiourea (47)—This compound was obtained from **45** by following the procedure described for the synthesis of **18** to afford a white solid in 82% yield: mp = 102 °C, ¹H NMR (CDCl₃) δ 7.38 (d, 2 H, *J* = 8.3 Hz, *t*-BuPh), 7.25 (d, 2 H, *J* = 8.3 Hz, *t*-BuPh), 7.22 (s, 1 H, H-5), 6.90 (s, 1 H, H-8), 6.73 (s, 1 H, NHSO₂), 6.18 (bs, 1 H, NH), 5.79 (bs, 1 H, NH), 5.53 (bs, 1 H, H-1), 4.53 (s, 2 H, CH₂NHCS), 3.82 (s, 3 H, OCH₃), 2.96 (s, 3 H, SO₂CH₃), 2.68 (m, 2 H, H-4), 2.02 (m, 1 H, H-2a), 1.7–1.9 (m, 3 H, H-3 & H-2b), 1.32 (s, 9 H, C(CH₃)₃); IR (KBr) 3433, 2959, 1635, 1540, 1457, 1338, 1153 cm⁻¹; MS *m/z* 476 (MH⁺); Anal. Calcd for C₂₄H₃₃N₃O₃S₂: C, 60.60; H, 6.99; N, 8.83; S, 13.48. Found: C, 60.84; H, 7.03; N, 8.80; S, 13.41.

Acknowledgments

This work was supported by grant R01-2007-000-20052-0 from the Basic Research Program of the Korea Science & Engineering Foundation and in part by the intramural research program of the NIH, National Cancer Institute, Center for Cancer Research.

References and Notes

- [1]. Szallasi A, Blumberg PM. Pharmacol. Rev. 1999; 51:159–211. [PubMed: 10353985]
- [2]. Tominaga M, Caterina MJ, Malmberg AB, Rosen TA, Gilbert H, Skinner K, Raumann BE, Basbaum AI, Julius D. Neuron. 1998; 21:531–543. [PubMed: 9768840]
- [3]. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. Nature. 1997; 389:816–824. [PubMed: 9349813]
- [4]. Zygmunt PM, Petersson J, Andersson DA, Chuang H-H, Sorgard M, Di Marzo V, Julius D, Hogestatt ED. Nature. 1999; 400:452–457. [PubMed: 10440374]
- [5]. Hwang SW, Cho H, Kwak J, Lee SY, Kang CJ, Jung J, Cho S, Min KH, Suh YG, Kim D, Oh U. Proc. Natl. Acad. Sci. USA. 2000; 97:6155–6160. [PubMed: 10823958]
- [6]. Walpole, CSJ.; Wrigglesworth, R. Capsaicin in the Study of Pain. Academic Press; San Diego, CA: 1993. p. 63
- [7]. Appendino G, Szallasi A. Life Sci. 1997; 60:681–696. [PubMed: 9064473]
- [8]. Szallasi A, Cruz F, Geppetti P. Trends in Mol. Med. 2006; 12:545–554. [PubMed: 16996800]
- [9]. Szallasi A, Cortright DN, Blum CA, Eid, S. R. Nature Reviews: Drug Discovery. 2007; 6:357–373.
- [10]. Westaway SM. J. Med. Chem. 2007; 50:2589–2596. [PubMed: 17489570]

- [11]. Wang Y, Szabo T, Welter JD, Toth A, Tran R, Lee J, Kang SU, Lee Y-S, Min KH, Suh Y-G, Park M-K, Park H-G, Park Y-H, Kim H-D, Oh U, Blumberg PM, Lee J. *Mol. Pharm.* 2002; 62:947–956. published erratum appears in *Mol. Pharmacol.* 2003, 63, 958.
- [12]. Wang Y, Toth A, Tran R, Szabo T, Welter JD, Blumberg PM, Lee J, Kang S-U, Lim J-O, Lee J. *Mol. Pharm.* 2003; 64:325–333.
- [13]. Lee J, Lee J, Kang M, Shin M-Y, Kim J-M, Kang S-U, Lim J-O, Choi H-K, Suh Y-G, Park H-G, Oh U, Kim H-D, Park Y-H, Ha H-J, Kim Y-H, Toth A, Wang Y, Tran R, Pearce LV, Lundberg DJ, Blumberg PM. *J. Med. Chem.* 2003; 46:3116–3126. [PubMed: 12825950]
- [14]. Suh Y-G, Lee Y-S, Min K-H, Park O-H, Kim J-K, Seung H-S, Seo S-Y, Lee B-Y, Nam Y-H, Lee K-O, Kim H-D, Park H-G, Lee J, Oh U, Lim J-O, Kang S-U, Kil M-J, Koo J-Y, Shin SS, Joo Y-H, Kim JK, Jeong Y-S, Kim S-Y, Park Y-H. *J. Med. Chem.* 2005; 48:5823–5836. [PubMed: 16134949]
- [15]. Lee J, Kang S-U, Kil M-J, Shin M, Lim J-O, Choi H-K, Jin M-K, Kim SY, Kim S-E, Lee Y-S, Min K-H, Kim Y-H, Ha H-J, Tran R, Welter JD, Wang Y, Szabo T, Pearce LV, Lundberg DJ, Toth A, Pavlyukovets VA, Morgan MA, Blumberg PM. *Bioorg. Med. Chem. Lett.* 2005; 15:4136–4142. [PubMed: 16005215]
- [16]. Lee J, Jin M-K, Kang S-U, Kim SY, Lee J, Shin M, Hwang J, Cho S, Choi Y-S, Choi H-K, Kim S-E, Suh Y-G, Lee Y-S, Kim Y-H, Ha H-J, Toth A, Pearce LV, Tran R, Szabo T, Welter JD, Lundberg DJ, Wang Y, Lazar J, Pavlyukovets VA, Morgan MA, Blumberg PM. *Bioorg. Med. Chem. Lett.* 2005; 15:4143–4150. [PubMed: 15993063]
- [17]. Chung J-U, Kim SY, Lim J-O, Choi H-K, Kang S-U, Yoon H-S, Ryu H, Kang DW, Lee J, Kang B, Choi S, Toth A, Pearce LV, Pavlyukovets VA, Lundberg DJ, Blumberg PM. *Bioorg. Med. Chem.* 2007; 15:6043–6053. [PubMed: 17629487]
- [18]. Dwyer CL, Holzapfel CW. *Tetrahedron.* 1998; 54:7843–7848.
- [19].

Figure 1.

Figure 2.

Scheme 1. Reagents and Conditions

(a) (Boc)₂O, NEt₃, CH₂Cl₂; (b) PCC, CH₂Cl₂; (c) TFA, CH₂Cl₂; (d) MsCl, Pyridine; (e) NH₂OH-HCl, Pyridine; (f) 10% Pd-C, H₂, c-HCl, MeOH; (g) 4-*t*-BuPhCH₂NCS, DMF

Scheme 2. Reagents and Conditions

(a) $\text{Cu}(\text{NO}_3)_2$, Ac_2O -ether (1:2); (b) 10% Pd-C, H_2 , MeOH; (c) MsCl, Pyridine; (d) $\text{NH}_2\text{OH}\cdot\text{HCl}$, Pyridine; (e) 10% Pd-C, H_2 , c-HCl, MeOH; (f) 4-*t*-BuPhCH₂NCS, DMF

Scheme 3. Reagents and Conditions

(a) $\text{Cu}(\text{NO}_3)_2$, Ac_2O -ether (1:2); (b) 10% Pd-C, H_2 , MeOH; (c) MsCl, Pyridine; (d) $\text{NH}_2\text{OH}\cdot\text{HCl}$, Pyridine; (e) 10% Pd-C, H_2 , c-HCl, MeOH; (f) 4-*t*-BuPhCH₂NCS, DMF

Table 1

n	R ₁	R ₂	K _i (nM) Binding Affinity ^c	EC ₅₀ (nM) Agonism ^c	K _i (nM) Antagonism ^c
1			63 (±10)	NE	53.9 (±8.7)
18	H	H	660 (±190)	NE	740 (±320)
19	H	H	1590 (±270)	NE	2640 (±720)
3			50 (±17)	32.4 (±5.3) ^a	3.4 (±1.0) ^b
32	OCH ₃	H	1820 (±260)	NE	1690 (±750)
33	OCH ₃	H	1750 (±200)	NE	4700 (±2600)
46	H	OCH ₃	3370 (±580)	NE	25000 (±6300)
47	H	OCH ₃	6900 (±2200)	WE ^a	NE

NE, no effect. WE, weak effect (quantitation of fractional agonism / antagonism is from 1–3 experiments).

^a only fractional calcium uptake compared with that induced by 300 nM capsaicin: **3**, 17%; **47**, 14%

^b only fractional antagonism: **3**, 88%

^c Values represent mean ± SEM from 3 or more experiments